The U.S. Food and Drug Administration (FDA) approved Rigel Pharmaceuticals' (NASDAQ:RIGL) Rezlidhia (olutasidenib) capsules to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. The FDA approval was backed by data from a phase 2 trial. "Rezlidhia provides a new and important, oral therapy option for patients who typically have a poor clinical outcome. Additionally, this approval greatly strengthens and expands Rigel's commercial hematology-oncology portfolio," said Rigel's President and CEO Raul Rodriguez. In August 2022, Rigel and Forma Therapeutics, a unit of Novo Nordisk (NVO) (OTCPK:NONOF), signed a licensing deal on Rezlidhia. Under the agreement, Rigel will be responsible to commercialize the drug in the U.S., and intends to work with potential partners to develop and commercialize the product outside the U.S.